BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15807714)

  • 1. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperproinsulinaemia in normoglycaemic lipodystrophic HIV-infected patients.
    Haugaard SB; Andersen O; Hales CN; Halsall I; Rosenfalck AM; Iversen J; Madsbad S
    Eur J Clin Invest; 2006 Jun; 36(6):436-45. PubMed ID: 16684128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy.
    Haugaard SB; Andersen O; Vølund A; Hansen BR; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):354-61. PubMed ID: 15730419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
    Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
    Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
    Toft-Nielsen M; Madsbad S; Holst JJ
    Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
    Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
    Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
    Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
    Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of insulin, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) secretion by octreotide has no effect on post-heparin plasma lipoprotein lipase activity.
    Ranganath LR; Beety JM; Morgan LM
    Horm Metab Res; 1999 Apr; 31(4):262-6. PubMed ID: 10333081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects.
    Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.
    Muscelli E; Mari A; Natali A; Astiarraga BD; Camastra S; Frascerra S; Holst JJ; Ferrannini E
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1144-50. PubMed ID: 16478775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
    Carr RD; Larsen MO; Winzell MS; Jelic K; Lindgren O; Deacon CF; Ahrén B
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E779-84. PubMed ID: 18612044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
    Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.